Abstract
There is an urgent need for new drugs to combat resistance to current chemotherapeutic treatments, especially anticancer and antimicrobial drugs. Design concepts based on the conjugation of active organic fragments are well-known. In their Minireview on page 8676 ff., P. Chellan and P. J. Sadler highlight the use of organometallic fragments to modify organic drugs and illustrate the potential for introducing novel mechanisms of action and restoring the activity of organic drugs against which resistance has developed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
